SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q/A
(Mark One)
[x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1995
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ___________
Commission file Number 0-15597
MARSAM PHARMACEUTICALS INC. AND SUBSIDIARY
(Exact name of registrant as specified in its charter)
DELAWARE 11-2718528
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification Number)
Building 31, Olney Avenue, Cherry Hill, New Jersey 08003
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:(609)424-5600
Indicate by check mark whether the Registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the Registrant was required to file
such reports) and (2) has been subject to such filing requirements
for the past 90 days. Yes X No
At March 31, 1995 (the close of the Registrant's first fiscal
quarter), there were 11,051,562 shares of the Registrant's common
stock, par value $. 01 per share (the "Common Stock") outstanding.
This 10-Q/A submission is to include a Financial Data Schedule
type EX-27 which was inadvertantly omitted in Marsam's prior
submission of Form 10-Q.
SIGNATURES
Pursuant to requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.
Marsam Pharmaceuticals Inc.
(Registrant)
Date: July 3, 1995 By: /S/ Marvin Samson
Marvin Samson
President, Treasurer and Chief
Executive Officer
Date: July 3, 1995 By: /S/ Richard Baron
Richard Baron
Vice President, Finance and
Chief Financial Officer
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1995
<PERIOD-END> MAR-31-1995
<CASH> 10,658,400
<SECURITIES> 4,210,000
<RECEIVABLES> 6,140,000
<ALLOWANCES> 162,400
<INVENTORY> 11,785,800
<CURRENT-ASSETS> 35,392,400
<PP&E> 27,555,500
<DEPRECIATION> 7,406,100
<TOTAL-ASSETS> 57,481,600
<CURRENT-LIABILITIES> 4,570,600
<BONDS> 0
<COMMON> 110,500
0
0
<OTHER-SE> 51,897,000
<TOTAL-LIABILITY-AND-EQUITY> 57,481,600
<SALES> 10,595,900
<TOTAL-REVENUES> 10,595,900
<CGS> 8,117,000
<TOTAL-COSTS> 8,117,000
<OTHER-EXPENSES> 2,057,500
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 1,208,900
<INCOME-TAX> 362,600
<INCOME-CONTINUING> 846,300
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 846,300
<EPS-PRIMARY> .08
<EPS-DILUTED> .08
</TABLE>
